Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...